Siltuximab
drugOn this page
Also known as CLLB8CNTO-328CNTO328Sylvant
Summary
Siltuximab (CHEMBL1743070) is an approved antibody (ATC L04AC11); indicated across 18 conditions including immune system disorder and castleman disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- ATC class: L04AC11
- Indications: 18 conditions
- Clinical trials: 32
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1743070 |
| Name | Siltuximab |
| Type | Antibody |
| Max phase | 4 |
| ATC | L04AC11 |
Also known as: CLLB8, CNTO-328, CNTO328, Siltuximab, Sylvant, SILTUXIMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
18 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| immune system disorder | 4 | MONDO:0005046 | EFO:0000540 |
| Castleman disease | 4 | MONDO:0015564 | EFO:1001332 |
| plasma cell myeloma | 3 | MONDO:0009693 | EFO:0001378 |
| severe acute respiratory syndrome | 3 | MONDO:0005091 | MONDO:0100096 |
| myelodysplastic syndrome | 2 | MONDO:0018881 | EFO:0000198 |
| prostate carcinoma | 2 | MONDO:0005159 | EFO:0001663 |
| prostate adenocarcinoma | 2 | MONDO:0005082 | EFO:0000673 |
| kidney cancer | 2 | MONDO:0002367 | MONDO:0002367 |
| neoplasm | 2 | MONDO:0005070 | EFO:0000616 |
| renal cell carcinoma | 1 | MONDO:0005086 | EFO:0000681 |
| monoclonal gammopathy | 1 | MONDO:0004960 | EFO:0000203 |
| acute myeloid leukemia | 1 | MONDO:0018874 | EFO:0000222 |
| non-Hodgkin lymphoma | 1 | MONDO:0018908 | EFO:0005952 |
| leukemia | 0 | MONDO:0005059 | EFO:0000565 |
| type 1 diabetes mellitus | 0 | MONDO:0005147 | MONDO:0005147 |
3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 32.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 17 |
| PHASE1 | 6 |
| PHASE1/PHASE2 | 3 |
| EARLY_PHASE1 | 3 |
| PHASE3 | 2 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07570173 | PHASE2/PHASE3 | RECRUITING | A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) |
| NCT04330638 | PHASE3 | COMPLETED | Treatment of COVID-19 Patients With Anti-interleukin Drugs |
| NCT04616586 | PHASE3 | TERMINATED | SILtuximab in Viral ARds (SILVAR) Study |
| NCT03315026 | PHASE2 | ACTIVE_NOT_RECRUITING | Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis |
| NCT04975555 | PHASE2 | ACTIVE_NOT_RECRUITING | Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy |
| NCT05684692 | PHASE2 | RECRUITING | Screening Trial for Pain Relief in Schwannomatosis (STARFISH) |
| NCT06470971 | PHASE2 | RECRUITING | Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial |
| NCT06679829 | PHASE2 | RECRUITING | A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant |
| NCT07106671 | PHASE2 | RECRUITING | A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma |
| NCT00385827 | PHASE2 | TERMINATED | A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC) |
| NCT00401843 | PHASE2 | COMPLETED | A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma |
| NCT00402181 | PHASE2 | COMPLETED | An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma |
| NCT00911859 | PHASE2 | COMPLETED | A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients |
| NCT01024036 | PHASE2 | COMPLETED | A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman’s Disease |
| NCT01400503 | PHASE2 | COMPLETED | A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman’s Disease |
| NCT01484275 | PHASE2 | COMPLETED | A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma |
| NCT01513317 | PHASE2 | TERMINATED | A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome |
| NCT01531998 | PHASE1/PHASE2 | COMPLETED | Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) |
| NCT02796859 | PHASE1/PHASE2 | UNKNOWN | Siltuximab in Schizophrenia |
| NCT04191421 | PHASE1/PHASE2 | COMPLETED | Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer |
| NCT04329650 | PHASE2 | COMPLETED | Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia |
| NCT04838860 | PHASE2 | TERMINATED | Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease |
| NCT06352866 | PHASE2 | WITHDRAWN | Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM |
| NCT06447376 | PHASE1 | RECRUITING | Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab |
| NCT06990711 | PHASE1 | RECRUITING | A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation |
| NCT01219010 | PHASE1 | COMPLETED | A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma |
| NCT01309412 | PHASE1 | TERMINATED | A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma |
| NCT05665725 | PHASE1 | COMPLETED | Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma |
| NCT05697510 | PHASE1 | UNKNOWN | Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM |
| NCT02641522 | EARLY_PHASE1 | COMPLETED | Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes |
| NCT02805868 | EARLY_PHASE1 | WITHDRAWN | Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis |
| NCT05316116 | EARLY_PHASE1 | TERMINATED | Siltuximab in Large Granular Lymphocytic Leukemia (LGLL) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).